Drug intelligence / Profile preview

RBS-003

Development stage: Unknown
Lead developer: RophiBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RBS-003 is a biosimilar monoclonal antibody candidate developed by RophiBio that targets the programmed cell death protein 1 (PD-1) receptor. As a biosimilar of pembrolizumab, it functions as an immune checkpoint inhibitor by blocking the interaction between PD-1 on T cells and its ligands, PD-L1 and PD-L2, on tumor cells. This blockade prevents the down-regulation of T-cell activity, thereby enhancing the immune system's ability to identify and eliminate cancer cells. RBS-003 is currently in early-stage clinical development for various oncological indications.

Other names: pembrolizumab biosimilar

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on RBS-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBS-003.

Explore the full profile